• Amgen adds antibody assets and R&D tech with $900M Teneobio acquisition

    1 month ago - By MedCity News

    Amgen is paying $900 million up front to acquire Teneobio, a biotech with technology for discovering and developing antibody drugs. Though Amgen already has its own antibody platform, the company says Teneobio's technology and drug assets will complement its own.
    Read more ...